Rise Advisors, LLC Design Therapeutics, Inc. Transaction History
Rise Advisors, LLC
- $249 Million
- Q3 2025
A detailed history of Rise Advisors, LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Rise Advisors, LLC holds 130 shares of DSGN stock, worth $958. This represents 0.0% of its overall portfolio holdings.
Number of Shares
130
Previous 130
-0.0%
Holding current value
$958
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding DSGN
# of Institutions
98Shares Held
34.1MCall Options Held
0Put Options Held
0-
Sr One Capital Management, LP6.53MShares$48.1 Million11.31% of portfolio
-
Logos Global Management LP San Francisco, CA3.66MShares$26.9 Million3.19% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.34MShares$24.6 Million0.05% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$17 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$14.4 Million0.62% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $411M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...